Cargando…

Immune modulation for cancer therapy

BACKGROUND: Immune modulation in cancer refers to a range of treatments aimed at harnessing a patient's immune system to achieve tumour control, stabilisation, and potential eradication of disease. A novel therapeutic drug class called immune checkpoint-blocking antibodies modulate T-cell pathw...

Descripción completa

Detalles Bibliográficos
Autores principales: Naidoo, J, Page, D B, Wolchok, J D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264429/
https://www.ncbi.nlm.nih.gov/pubmed/25211661
http://dx.doi.org/10.1038/bjc.2014.348
_version_ 1782348741267685376
author Naidoo, J
Page, D B
Wolchok, J D
author_facet Naidoo, J
Page, D B
Wolchok, J D
author_sort Naidoo, J
collection PubMed
description BACKGROUND: Immune modulation in cancer refers to a range of treatments aimed at harnessing a patient's immune system to achieve tumour control, stabilisation, and potential eradication of disease. A novel therapeutic drug class called immune checkpoint-blocking antibodies modulate T-cell pathways that regulate T cells and have the potential to reinvigorate an antitumour immune response. Ipilimumab was the first FDA-approved immune checkpoint antibody licensed for the treatment of metastatic melanoma (MM) and blocks a checkpoint molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). METHODS: Herein we review the preclinical and clinical development of ipilimumab. We outline the mode of action of these agents and other immune checkpoint inhibitors, the management of their toxicities, and how to adequately assess response to treatment. RESULTS: As a result of these data, a number of other antibodies that block novel checkpoint molecules including programmed death-1 (PD-1), and corresponding ligands such as programmed death ligand-1 (PD-L1) are under preclinical and clinical development, and have demonstrated activity in multiple tumour types. CONCLUSIONS: This review will summarise the mechanism of action and clinical development of immune checkpoint antibodies, as well as lessons learned in the management and assessment of patients receiving these agents.
format Online
Article
Text
id pubmed-4264429
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-42644292014-12-16 Immune modulation for cancer therapy Naidoo, J Page, D B Wolchok, J D Br J Cancer Minireview BACKGROUND: Immune modulation in cancer refers to a range of treatments aimed at harnessing a patient's immune system to achieve tumour control, stabilisation, and potential eradication of disease. A novel therapeutic drug class called immune checkpoint-blocking antibodies modulate T-cell pathways that regulate T cells and have the potential to reinvigorate an antitumour immune response. Ipilimumab was the first FDA-approved immune checkpoint antibody licensed for the treatment of metastatic melanoma (MM) and blocks a checkpoint molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). METHODS: Herein we review the preclinical and clinical development of ipilimumab. We outline the mode of action of these agents and other immune checkpoint inhibitors, the management of their toxicities, and how to adequately assess response to treatment. RESULTS: As a result of these data, a number of other antibodies that block novel checkpoint molecules including programmed death-1 (PD-1), and corresponding ligands such as programmed death ligand-1 (PD-L1) are under preclinical and clinical development, and have demonstrated activity in multiple tumour types. CONCLUSIONS: This review will summarise the mechanism of action and clinical development of immune checkpoint antibodies, as well as lessons learned in the management and assessment of patients receiving these agents. Nature Publishing Group 2014-12-09 2014-09-11 /pmc/articles/PMC4264429/ /pubmed/25211661 http://dx.doi.org/10.1038/bjc.2014.348 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Minireview
Naidoo, J
Page, D B
Wolchok, J D
Immune modulation for cancer therapy
title Immune modulation for cancer therapy
title_full Immune modulation for cancer therapy
title_fullStr Immune modulation for cancer therapy
title_full_unstemmed Immune modulation for cancer therapy
title_short Immune modulation for cancer therapy
title_sort immune modulation for cancer therapy
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264429/
https://www.ncbi.nlm.nih.gov/pubmed/25211661
http://dx.doi.org/10.1038/bjc.2014.348
work_keys_str_mv AT naidooj immunemodulationforcancertherapy
AT pagedb immunemodulationforcancertherapy
AT wolchokjd immunemodulationforcancertherapy